Linda M. Henricks

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 403 citations · Full text

Medicine, Prospective Safety Analysis, Cancer Management +9

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

Didier Meulendijks, Linda M. Henricks, Bart Jacobs et al. · British Journal of Cancer · 2017 · 119 citations · Full text

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

Linda M. Henricks, Frans L. Opdam, J. H. Beijnen et al. · Annals of Oncology · 2017 · 89 citations · Full text

Drug Safety, Therapeutic Drug Monitoring, Oncology +6

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 87 citations · Full text

Upfront Dpyd, Medicine, Metronomic Therapy +8

RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth

Philippe Depeille, Linda M. Henricks, Robert A. H. van de Ven et al. · Nature Cell Biology · 2015 · 72 citations · Full text

Cancer Research, Signaling Pathway, Proliferative Egfr–sos1–ras Signals +9